Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998299 | 0.84 | NR1H2 (0.44) | NR1H2NR1H3FFAR1FFAR4TRPV1 | |
| SCHEMBL2000114 | 0.83 | NR1H2 (0.48) | NR1H2NR1H3CA12CA2CA9 | |
| SCHEMBL1999999 | 0.81 | NR1H2 (0.52) | NR1H2NR1H3CA12CA2CA9 | |
| SCHEMBL2002366 | 0.78 | NR1H2 (0.42) | NR1H2NR1H3HDAC1HDAC2 | |
| SCHEMBL2003178 | 0.77 | NR1H2 (0.53) | NR1H2NR1H3CA12CA2CA9 | |
| SCHEMBL2005976 | 0.77 | NR1H2 (0.53) | NR1H2NR1H3CA12CA2CA9 | |
| SCHEMBL2000315 | 0.77 | NR1H2 (0.53) | NR1H2NR1H3CA12CA2CA9 | |
| SCHEMBL1998742 | 0.77 | NR1H2 (0.41) | NR1H2NR1H3TRPV1SCN9A | |
| SCHEMBL2000548 | 0.77 | NR1H2 (0.45) | NR1H2NR1H3CA12CA2CA9 | |
| SCHEMBL2000527 | 0.76 | NR1H2 (0.44) | NR1H2NR1H3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | claimed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | THE ROCKEFELLER UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885NTRK1 3158/4885 |
| US-11648220-B2 | Methods for the treatment of myeloid derived suppressor cells related disorders | NR1H3, NR1H2, MCL1 | NR1H2 2/4885NR1H3 1/4885NTRK1 1739/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NR1H2 2/4885NR1H3 1/4885NTRK1 1739/4885 |
| US-20190029984-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | NR1H2 2/4885NR1H3 1/4885NTRK1 1739/4885 |
| US-20190125745-A1 | TREATMENT AND DIAGNOSIS OF CANCER | NR1H4, NR1H3, NR1H2 | NR1H2 3/4885NR1H3 2/4885NTRK1 1607/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885NTRK1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.